MONTREAL, QUEBEC--(Marketwire - May 12, 2008) - Thallion Pharmaceuticals Inc. (TSX:TLN) today announced it has received authorization from the Therapeutic Products Directorate of Health Canada to initiate a Phase II clinical trial evaluating TLN-4601 as a monotherapy treatment for patients with glioblastoma multiforme (GBM), an advanced form of brain cancer, as a second line therapy.
